12 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 32815796 | Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis. | 2022 Jan | 1 |
2 | 35335157 | Computational Screening of Phenylamino-Phenoxy-Quinoline Derivatives against the Main Protease of SARS-CoV-2 Using Molecular Docking and the ONIOM Method. | 2022 Mar 9 | 1 |
3 | 33781188 | Protein-Ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2. | 2021 | 1 |
4 | 33842834 | Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs. | 2021 Mar | 1 |
5 | 34320905 | One microsecond MD simulations of the SARS-CoV-2 main protease and hydroxychloroquine complex reveal the intricate nature of binding. | 2021 Jul 29 | 2 |
6 | 34345611 | Working goal of Brazilein sappan wood as a candidate for SARS-coV-2 antivirus drug against spike (S) glycoprotein, papain-like proteinase, and main protease: In silico study. | 2021 Jul-Sep | 1 |
7 | 34537554 | Investigation of structural analogs of hydroxychloroquine for SARS-CoV-2 main protease (Mpro): A computational drug discovery study. | 2021 Dec | 2 |
8 | 34658419 | Synthesis, crystal structure, computational study and anti-virus effect of mixed ligand copper (II) complex with ONS donor Schiff base and 1, 10-phenanthroline. | 2021 Dec 15 | 1 |
9 | 34842499 | Structural and theoretical investigations, Hirshfeld surface analysis and anti-SARS CoV-2 of nickel (II) coordination complex. | 2021 Nov 29 | 1 |
10 | 32738306 | In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection. | 2020 Sep | 2 |
11 | 33051297 | Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs. | 2020 Nov 3 | 1 |
12 | 33176880 | Pharmacophore modelling of vanillin derivatives, favipiravir, chloroquine, hydroxychloroquine, monolaurin and tetrodotoxin as MPro inhibitors of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). | 2020 Nov 11 | 1 |